• 1. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 2. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives Difurocoumarocyclopentenones

Recent Advances in the Study of Aflatoxin Q1 (52819-96-2): Implications for Toxicology and Biomedicine

Aflatoxin Q1 (CAS: 52819-96-2), a hydroxylated metabolite of aflatoxin B1 (AFB1), has garnered increasing attention in recent years due to its unique toxicological profile and potential biomedical applications. This research brief synthesizes the latest findings on this compound, with a focus on its metabolic pathways, molecular mechanisms, and emerging detection methodologies. Recent studies have elucidated the cytochrome P450-mediated formation of AFQ1 from AFB1, revealing species-specific differences in metabolic activation that may explain variations in susceptibility to aflatoxin-induced hepatotoxicity.

Cutting-edge analytical techniques, particularly high-resolution mass spectrometry coupled with liquid chromatography (LC-HRMS), have enabled more precise quantification of AFQ1 in biological matrices. A 2023 study published in Analytical and Bioanalytical Chemistry demonstrated a novel stable isotope dilution assay capable of detecting AFQ1 at concentrations as low as 0.05 pg/mg in liver tissue, representing a 40% improvement in sensitivity over previous methods. This advancement is particularly significant for monitoring human exposure in regions with high aflatoxin contamination in food supplies.

Emerging evidence suggests AFQ1 may serve as both a biomarker of aflatoxin exposure and a potential therapeutic target. Research from the National Cancer Institute has identified specific protein adducts formed by AFQ1 that correlate strongly with hepatocellular carcinoma risk. Interestingly, several recent studies have explored the paradoxical antioxidant properties of AFQ1 at low concentrations, with a 2024 Cell Chemical Biology paper reporting its ability to activate Nrf2-mediated cytoprotective pathways in vitro.

The development of AFQ1-specific antibodies has opened new avenues for rapid detection. A team at ETH Zurich recently engineered a single-chain variable fragment (scFv) with 100-fold greater affinity for AFQ1 than conventional polyclonal antibodies, as detailed in their Nature Biotechnology publication. This breakthrough could lead to point-of-care diagnostic tools for aflatoxin exposure monitoring in resource-limited settings.

From a regulatory perspective, the European Food Safety Authority (EFSA) recently updated its risk assessment guidelines to include AFQ1-specific toxic equivalency factors. This change reflects growing recognition of AFQ1's distinct toxicological properties compared to its parent compound. Concurrently, the FDA has approved two new IND applications for AFQ1-targeted therapies in preclinical development for liver fibrosis.

Future research directions highlighted in recent literature include the exploration of AFQ1-protein interactions through cryo-EM structural studies and the development of AFQ1-conjugated nanoparticles for targeted drug delivery. A particularly promising 2024 study in Science Advances demonstrated the potential of AFQ1-functionalized liposomes to selectively deliver chemotherapeutic agents to CYP3A4-expressing tumor cells.

• 32215-02-4(Aflatoxin P1)
• 1162-65-8(Aflatoxin B1)
• 29611-03-8(Aflatoxicol)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)